A Study of Mirikizumab in Participants With Plaque Psoriasis

Status:	Recruiting
Conditions:	Psoriasis
Therapuetic Areas:	Dermatology / Plastic Surgery
Healthy:	No
Age Range:	18 - Any
Updated:	4/5/2019
Start Date:	October 23, 2018
End Date:	September 22, 2019
Contact:	There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Email:	ClinicalTrials.gov@lilly.com
Phone:	1-317-615-4559

Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis

This study is known as a "drug interaction study." The purpose is to learn how commonly used
drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and
their breakdown products get into the bloodstream after taking a "cocktail" (combination) of
them before and after multiple doses of mirikizumab.

The study will last about 23 weeks for each participant. Screening must be completed within 4
weeks prior to study start.

Inclusion Criteria:

- Males and females with chronic plaque psoriasis for at least 6 months who are
candidates for systemic therapy or phototherapy

- Have greater than or equal to (≥) 10 percent body surface area (BSA) involvement at
screening and first admission to the clinical site

Exclusion Criteria:

- Pregnant or nursing (lactating)

- History of an ongoing, chronic or recurrent infectious disease, or evidence of
tuberculosis infection

- Have major surgery within 8 weeks prior to first admission to the clinical site or
during the study

- Have a history of lymphoma, leukemia, or any malignancy

- Require treatment with the cocktail drugs within 14 days prior to the first
administration of the drug cocktail through the end of Week 12 assessments

- Have participated in any other study with mirikizumab

We found this trial at

sites

Avail Clinical Research